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Fatal HIV
Encephalitis in 
HIV-Seronegative 
Patients
To the Editor: Acute encephalitis 
is rarely seen in patients infected with 
HIV (1). In addition, HIV in patients 
who are seronegative is extremely 
rare, particularly in the setting of cur-
rent screening ELISAs (2). We report 
a case of encephalitis and HIV in the 
same patient, which resulted in death.
A 44-year-old Caucasian woman 
sought treatment at our hospital with a 
1-week history of fever, unsteady gait, 
and progressive confusion. Her medi-
cal history included hypothyroidism, 
depression, and chronic alcohol abuse. 
The patient’s fi rst tests for HIV were 
negative at 19 and 12 months prior 
to admission during routine intake 
screening for jail inmates (Abbott HIV 
AB HIV-1/HIV-2 [rDNA] enzyme im-
munoassay [EIA] kit; Abbott Labo-
ratories, Abbott Park, IL, USA). Six 
months before admission, the patient 
had a viral exanthem of blistering rash 
on her lips, palate, and chest.  Two 
weeks later, she had oral thrush and 
a leukocyte count of 1,700 cells/μL. 
An HIV ELISA result was negative. 
Three months before admission, she 
was admitted to a different hospital 
for weakness, abdominal pain, inter-
mittent fever, diarrhea, persistent oral 
candidiasis, and ethanol withdrawal. 
She had leukopenia and thrombocy-
topenia. A fourth HIV ELISA result 
was negative. The patient had been ad-
mitted to our hospital one week before 
the current admission with symptoms 
of fever, confusion, and urinary tract 
infection. Lumbar puncture showed an 
elevated protein level (106 mg/dL). A 
fi fth HIV test result 6 days before most 
recent admission was negative. Five 
days before admission, she had been 
discharged to a rehabilitation facility.
On this hospitalization, she had 
fatigue, headache, disequilibrium, 
dysarthria, and blurred vision.  Initial 
examination showed fever of 101.3°F, 
poor word recall, and a wide-based 
gait. Laboratory tests showed mild 
anemia and a leukocyte count of 2 × 
103 cells/μL.
Over the next few days the pa-
tient’s fever persisted and her mental 
status fl uctuated.  Tests on hospital 
day 2 showed a CD4 count of 101/mL 
(16.9%). Magnetic resonance imag-
ing (MRI) of the brain showed diffuse 
symmetric white matter disease (Fig-
ure, panel A).  Samples sent on hos-
pital day 9 eventually showed wild-
type HIV with a viral load >500,000 
copies/mL. Repeat cerebrospinal fl uid 
(CSF) test results were negative for 
cryptoccocus antigen, and PCR results 
were negative for cytomegalovirus, 
herpes simplex virus (HSV), and JC 
polyoma virus. The next day, a sixth 
HIV ELISA result was negative. The 
serum level of HIV p24 antigen was 
202 pg/mL.
On hospital day 13, the patient 
began treatment with zidovidine, la-
muvidine, didanosine, and nevirap-
ine. Within 24 hours, seizures and 
catatonia developed in the patient. An 
electroencephalogram showed diffuse 
wave form slowing. A repeat MRI 
showed worsened white matter dis-
ease (Figure, panel B). The result of 
a seventh HIV screening ELISA per-
formed on hospital day 15 was nega-
tive. Two days later, the HIV viral load 
was 241,789 copies/mL. On hospital 
day 19, her serum levels were within 
normal limits: immunoglobulin (Ig) 
M level (164 mg/dL), IgG level (1,440 
mg/dL), a 3× normal IgA level (1,060 
mg/dL), and no oligoproteins. The 
CSF had an IgG level >10× normal 
(72 mg/dL), elevated IgG levels for 
HSV1 (1:160) and HSV2 (1:40), was 
negative for virus culture, and showed 
a negative PCR result for JC polyoma 
virus. On hospital day 23, the eighth 
HIV ELISA result was negative. The 
Abbott HIVAB HIV-1/HIV-2 (rDNA) 
EIA was used throughout the hospital-
ization. On hospital day 24, supportive 
care was withdrawn and the patient 
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died. Throughout her hospitalization, 
blood, urine, and CSF cultures re-
mained sterile.
Autopsy showed acute HIV en-
cephalopathy and cerebral vasculopa-
thy. The fi ndings included multifocal 
microglial nodules, perivascular in-
fl ammatory cells, vasculopathy with 
mural fi brosis and perivascular he-
mosiderin deposition, degeneration of 
the central white matter, and neuronal 
apoptosis (Figure, panel C). She also 
had Pneumocytis jiroveci pneumonia 
and hepatosteatosis without cirrhosis. 
There are several possible expla-
nations for the patient’s HIV serocon-
version failure. The fi rst explanation 
is that the patient was subacutely in-
fected but had a retarded humoral re-
sponse. Delayed seroconversion has 
been documented up to 42 months 
after infection (3), but this seems un-
likely with current ultrasensitive as-
says. Another possibility is that she 
was infected with a strain undetect-
able by screening ELISAs, such as 
HIV-1 Group N or a rare Group M 
subtype recombinant variant. This hy-
pothesis also seems unlikely because 
of the rarity and geographic distribu-
tion of these strains (4). A third pos-
sibility is transient seroconversion 
with reversion to seronegative status 
(5,6). However, given the number and 
frequency of screening tests in this 
case, even transient seroconversion 
would probably have been detected. 
Another hypothesis, one consistent 
with the patient’s rapid demise, is 
infection with a particularly virulent 
HIV variant, which led to rapid immu-
nocompromise and failure of serocon-
version. Such infections have been ob-
served in rapid progressors, in which 
CD4+ T-cell depletion is so swift that 
B cells receive no T-cell help and are 
therefore not able to mount an effec-
tive immune response (7). In addition, 
chronic alcoholism may have contrib-
uted to immune failure and a rapidly 
progressive disease course (8–10).  
This case raises several disturb-
ing and interesting questions and pos-
sible avenues for future research. The 
diagnosis of acute HIV encephalopa-
thy with a CD4 count of 100 cells/μL 
raises the likelihood that this patient 
was infected with at least 1 strain con-
taining particularly neurotropic prop-
erties, possibly with X4 or R5X4 tro-
pism, or that her brain was particularly 
primed for HIV-induced damage. Un-
derstanding the neurotropic properties 
of different strains of HIV may help 
prevent similar adverse outcomes in 
other patients.   
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Figure. Brain magnetic resonance imaging (MRI) and autopsy fi ndings for the patient. Brain MRI showed diffuse white matter disease 
on hospital day 2 (A) and marked progression on hospital day 14 (B). Autopsy histopathologic analysis showed microglial nodules, 
multinucleated giant cells (arrow), perivascular infl ammatory cells, vasculopathy with mural fi brosis, perivascular hemosiderin deposition, 
degeneraton of the central white matter, and neuronal apoptosis (C). 
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Classical ctxB in 
Vibrio cholerae O1, 
Kolkata, India
To the Editor: Among the 206 
serogroups of Vibrio cholerae, O1 and 
O139 are associated with epidemic 
cholera. Serogroup O1 is classifi ed 
into 2 biotypes, classical and El Tor. 
Conventionally, the 2 biotypes can be 
differentiated on the basis of a set of 
phenotypic traits. Comparative ge-
nomic analysis has shown variations 
in different genes between these bio-
types (1). Cholera toxin (CT), the ma-
jor toxin responsible for the disease 
cholera, has 2 epitypes or immunolog-
ic forms, CT1 and CT2 (2). Another 
classifi cation recognizes 3 genotypes 
on the basis of the ctxB gene sequence 
variation (3). In the past few years, a 
new emerging form of V. cholerae O1, 
which possesses traits of both classical 
and El Tor biotypes, has been isolated 
in Bangladesh (4,5), Mozambique 
(6), Vietnam, Hong Kong, Japan, and 
Zambia (7). These strains were vari-
ously labeled as Matlab variants, hy-
brids, or altered El Tor strains.
Our study analyzed, in chrono-
logical order, strains of V. cholerae O1 
that were isolated over 17 years (1989–
2005). We used strains isolated during 
diarrhea surveillance conducted at the 
Infectious Diseases Hospital, Kol-
kata (Calcutta), to determine precisely 
when the hybrid strains appeared in 
this region. A total of 171 strains of V. 
cholerae O1, which were selected to 
cover different months of each year, 
were included in this study, along with 
2 reference strains for classical and El 
Tor biotypes. The V. cholerae strains 
were confi rmed serologically by slide 
agglutination using a specifi c polyva-
lent antiserum to V. cholerae O1.
We focused on the ctxB gene. 
The strains were examined by mis-
match amplifi cation mutation assay 
(MAMA)–based PCR for detecting the 
ctxB allele; a common forward primer 
was used for 2 alleles, FW-Com (5′-
ACTATCTTCAGCATATGCACAT-
GG-3′); and 2 allele-specifi c prim-
ers, Re-cla (5′-CCTGGTACTTCTAC
TTGAAACG-3′) and Re-elt (5′-
CCTGGTACTTCTACTTGAAA
CA-3′), were used for classical and El 
Tor biotypes, respectively (8). Results 
of the MAMA-PCR are summarized 
in the Table. All of the 123 V. chol-
erae O1 strains from 1995 through 
2005 yielded only the classical type of 
ctxB, which indicates that since 1995 
the classical type has completely re-
placed the El Tor type ctxB (Table). 
To reconfi rm our PCR-based results, 
we selected 25 representative strains 
for DNA sequencing of the ctxB gene. 
The deduced amino acid sequences 
were aligned with the CtxB sequences 
of reference strains N16961 (El Tor) 
and O395 (classical). The deduced 
amino acid sequences of all 25 strains 
were identical to those of the classi-
cal reference strain; histidine was at 
position 39 and threonine was at posi-
tion 68. Thus, the results from DNA 
sequencing of the ctxB gene confi rmed 
the MAMA-PCR results.
 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 15, No. 1, January 2009 131 
Table. Prevalence of different types of ctxB alleles among Vibrio cholerae O1 strains, 
Kolkata, India, 1989–2005 
No. alleles Year 
isolated
No. strains 
tested Classical ctxB El Tor ctxB Classical + El Tor ctxB
1989 6 0 6 0
1990 7 4 3 0
1991 10 8 0 2*
1992 10 4 5 1*
1993 6 4 2 0
1994 9 8 1 0
1995 23 23 0 0
1996 10 10 0 0
1997 10 10 0 0
1998 10 10 0 0
1999 10 10 0 0
2000 10 10 0 0
2001 10 10 0 0
2002 10 10 0 0
2003 10 10 0 0
2004 10 10 0 0
2005 10 10 0 0
*These strains carry the ctxB gene for El Tor, as well as classical strains. 
